Prospective study of UDP-glucuronosyltransferase (UGT) 2B17 genotype and exemestane (Exe) pharmacokinetics (PK) and pharmacodynamics (PD) in Asian, hormone receptor (HR) positive, metastatic breast cancer (MBC) patients.
Walsh R, Lee S, Seng K, Wang L, Ho G, Ow S, Kumarakulasinghe N, Sundar R, Lee X, Yap H, Jeyasekharan A, Pang A, Ho J, Tan C, Lim Y, Malik R, Wan Ishak W, Goh B, Tai B, Wong A. Prospective study of UDP-glucuronosyltransferase (UGT) 2B17 genotype and exemestane (Exe) pharmacokinetics (PK) and pharmacodynamics (PD) in Asian, hormone receptor (HR) positive, metastatic breast cancer (MBC) patients. Journal Of Clinical Oncology 2017, 35: 1056-1056. DOI: 10.1200/jco.2017.35.15_suppl.1056.Peer-Reviewed Original ResearchClinical benefit rateMetastatic breast cancerHormone receptorsMetastatic breast cancer patientsUDP-glucuronosyltransferaseClinical treatment efficacyGlucuronidation in vitroUGT2B17 genotypeBenefit rateClinical benefitProspective studyBreast cancerActive metabolitePK dataPD biomarkersTreatment efficacyPatientsPharmacodynamicsPD effectsResponse rateUGT2B17C maxActivity indexPharmacokineticsSignificant PD